Showing 15 posts of 110 posts found.


Biogen to acquire Reata Pharmaceuticals

July 31, 2023
Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …

Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

Biogen Phase III choroideremia study did not meet primary endpoint

June 15, 2021
Manufacturing and Production Biogen, choroideremia, phase III

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …


Biogen fails to meet primary endpoint in XLRP study

May 17, 2021
Sales and Marketing Biogen, Clinical Trail

Biogen have released topline results from its Phase2/3 Xirius study of cotoretigene toliparvovec (BIIB112) as a gene therapy for patients …


FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021
Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …


Researchers and pharma companies partner to investigate new schizophrenia treatment

January 21, 2021
Biogen, Boehringer Ingelheim

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …


Biogen’s IM Plegridy gets EU approval

January 6, 2021
Research and Development Biogen, multiple sclerosis

The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …


Biogen agrees to pay $22m to settle kickback allegations

December 18, 2020
Medical Communications Biogen, multiple sclerosis

Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …


FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis

October 7, 2020
Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis

Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …


Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

August 20, 2020
Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …


Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …


100 coronavirus cases linked to Biogen-hosted event in Boston, State of Massachusetts confirms

March 18, 2020
Manufacturing and Production, Medical Communications, Research and Development Biogen, coronavirus, pharma

It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …


Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts

March 9, 2020
Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma

Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …


Biogen stock surges following patent victory over Mylan for Tecfidera

February 6, 2020
Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …


Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

Latest content